New pill shows promise in slowing advanced breast cancer
NCT ID NCT06301438
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a drug called dalpiciclib in people with a specific type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how long the drug can keep the cancer from growing and what side effects it causes. About 103 participants will take dalpiciclib as a pill for 21 days on, 7 days off. Researchers will track disease progression and any adverse events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dalpiciclib (a CDK4/6 inhibitor taken as a pill)
What this could lead to
If successful, this study could show that dalpiciclib helps control advanced breast cancer for longer, offering a new treatment option for people with this type of cancer.
What could go wrong
This is a real-world study, not a controlled trial, so results may be less reliable. The drug may not work for everyone and can cause side effects like low blood cell counts or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITINGShanghai, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••